Xencor Inc (XNCR)
Receivables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 110,493 | 168,338 | 164,579 | 275,111 | 122,694 |
Receivables | US$ in thousands | — | — | — | — | — |
Receivables turnover | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $110,493K ÷ $—K
= —
The receivables turnover ratio for Xencor Inc has not been provided for the years 2020 to 2024. This ratio is typically used to assess the efficiency of a company in collecting its accounts receivable during a specific period. Without the specific turnover ratios for these years, it is challenging to evaluate the effectiveness of Xencor's accounts receivable management and the speed at which it is able to convert its receivables into cash. Monitoring this ratio over time could provide insights into Xencor's credit policies, collection efforts, and overall liquidity position.
Peer comparison
Dec 31, 2024
Company name
Symbol
Receivables turnover
Xencor Inc
XNCR
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
4.05
Amphastar P
AMPH
5.37
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
51.60
Biomarin Pharmaceutical Inc
BMRN
4.31
Bristol-Myers Squibb Company
BMY
4.49
Catalyst Pharmaceuticals Inc
CPRX
—